•  
sterna biologicals home

sterna biological to participate in upcoming international conferences in H1 2018

pdf Download this release as PDF 

Marburg, Germany, 01 February 2018 - sterna biologicals GmbH & Co. KG (sterna), an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases, today announces its participation in the following key scientific and partnering conferences in the first half of 2018:

13th Congress of ECCO - European Crohn's and Colitis Organisation
Date: February 14-17, 2018 in Vienna, Austria

17th European Dermatology Congress
Date: March 01-03, 2018 in Paris, France

AAAAI/WAO Joint Congress - American Academy of Allergy, Asthma & Immunology and World Allergy Organisation
Date: March 02-05, 2018 in Orlando, USA

BIO-Europe Spring
Date: March 12-14, 2018 in Amsterdam, The Netherlands

German Respiratory Society - 59th Annual Meeting
Date: March 14-17, 2018 in Dresden, Germany

12th Global Gastroenterologists Meeting
Date: March 15-16, 2018 in Barcelona, Spain

10th Georg Rajka International Symposium on Atopic Dermatitis (ISAD)
Date: April 11-13, 2018 in Utrecht, The Netherlands

International Investigative Dermatology
Date: May 16-19, 2018 in Orlando, USA

ATS 2018 - American Thoracic Society
Date: May 18-23, 2018 in San Diego, USA

EAACI Congress 2018 - European Academy of Allergy and Clinical Immunology
Date: May 26-30, 2018 in Munich, Germany

2018 BIO International Convention
Date: June 04-07, 2018 in Boston, USA

67th Annual Meeting of Japanese Society of Allergology 2018
Date: June 22-24, 2018 in Chiba, Japan

World Congress on Gastroenterology and Hepatology
Date: June 25-27, 2018 in Stockholm, Sweden

As further details on the conferences and presentations are available, this information will be updated on the Company's website: http://www.sterna-biologicals.com/. Parties interested in meeting the sterna representatives at one of these conferences, please contact Derya Akar at This e-mail address is being protected from spambots. You need JavaScript enabled to view it .

ABOUT STERNA BIOLOGICALS

Sterna biologicals GmbH & Co. KG is an innovative clinical-stage immunology company developing novel treatments for chronic inflammatory diseases such as asthma, chronic obstructive pulmonary disease (COPD), atopic dermatitis, and ulcerative colitis. By targeting transcription factors that play a pivotal role in regulating Th1 and Th2 inflammatory mechanisms, the Company's proprietary DNAzyme-based drug candidates can intervene with upstream inflammatory processes and address related diseases more effectively. Sterna has currently four programs in Phase II development.

CONTACT
Christian Pangratz
Chief Executive Officer
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
sterna biologicals GmbH & Co. KG
Bismarckstrasse 7
35037 Marburg
Tel.: +49 (0)6421.98 30 05 0

For media enquiries:
Anne Hennecke
MC Services AG
This e-mail address is being protected from spambots. You need JavaScript enabled to view it
Tel.: +49 (0)211.52 92 52 22

© sterna biologicals GmbH & Co. KG • Bismarckstraße 7 • D-35037 Marburg